



# CANCER TREATMENT RESEARCH

Edited by Joseph Aisner  
and Paul Chang



T 136 A 1

## INTRODUCTION

In recent years the field of cancer treatment has been burgeoning with ever expanding interest and commitments to research and therapy. Besides the large number of specialty journals and publications devoted to cancer related fields, nearly every general medical journal contains one or more articles related to cancer treatment and research. Another example of this expanding commitment and interest is reflected in the Internal Medicine subspecialty of Medical Oncology which, since its recognition as a subspecialty in 1973, has become the secondmost populated subspecialty, second only to cardiology. This burgeoning interest and commitment is obviously appropriate in view of the prevalence and incidence of the various cancers. These diseases constitute, after all, some of the most important and devastating problems of civilized man.

It has been particularly gratifying to those involved with cancer research and therapy to observe the increasing interest in these diseases being translated into real improvements in patient care - improvements in length of survival, improvements in quality of survival, and improvements in palliative care. One need only look at Hodgkin's disease to observe the high rate of cure now routinely obtained whereas, in the past, many patients' disease continued to progress with fatal consequences. Some of these improvements came about through better staging techniques, and other improvements, as will be discussed in the chapter on Hodgkin's, came about from the application of early chemotherapy. Further research in Hodgkin's disease is still going on in order to improve results and decrease treatment related complications.

Another example of the improvements derived in recent years from ongoing treatment research studies has been the realization of improved survival from the application of early or "adjuvant" treatment of micrometastases. Based on solid evidence in the animal tumor systems, the early multimodal treatment of bulk and micrometastatic disease has led to marked improvements in survival of patients with Wilms' tumor, pediatric rhabdomyosarcoma, and osteosarcoma as well as breast cancer. With the principle and the concepts of early treatment of micrometastases firmly established, new studies are being rapidly carried forward on a variety of diseases such as gastric cancer in which active therapy of advanced disease has been identified. In other tumors, such as pancreatic cancer, active drugs and combinations are being sought in the advanced stage of the disease with the aim of eventually applying such active drugs or treatment modalities earlier in the course of the disease.

Parallel to such advances in therapy, a large effort at earlier diagnosis is being made in order to institute therapy of cancer at its earliest and most

potentially curable state. Such diagnostic efforts would also lead to methods which could help evaluate, measure and follow difficult tumors. Thus newer methods or new applications of established methods (such as those discussed in the chapters on mammography) allow for the identification of early cancers. Other techniques such as CAT scans could allow for the identification, measurement and sequential follow-up of difficult tumors such as pancreatic carcinoma, in which measurable disease has been a stumbling block in the past for evaluating potentially active agents or treatments.

This volume, derived in part from a past continuing education symposium held by the Baltimore Cancer Research Program, has brought together a group of medical investigators involved in cancer research to review their respective areas from the standpoint of actual and anticipated advances in cancer treatment. The spectrum of the material thus ranges from basic medical and scientific information necessary for staging and therapy (as discussed in the chapters on non-Hodgkin's lymphomas) to the anticipated changes within the next decade. The chapters on head and neck cancers deal with treatment for this group of cancers for which newer agents and treatment approaches, such as combined modality therapy or pre-operative application of chemotherapy, will hopefully lead to marked improvements. The discussion of abdominal CAT scans naturally leads into discussion of intra-abdominal cancers of the stomach, pancreas and bladder. The discussions of mammography for the early detection of breast cancer lead into the chapters dealing with newer approaches for the primary management of breast cancer with either radiotherapy or lesser surgical procedures. The chapters on the early therapy of micrometastases review the striking success seen in the pediatric tumors as well as the principles involved in the design and management of "adjuvant" treatment programs. Other discussions include cell kinetics and their use in predicting optimal application of therapy, and a discussion of unconventional treatments in cancer. With these reviews of a wide spectrum of cancer diagnosis and treatment, we hope to present a very large body of information in a relatively compact and easily digested format.

Joseph Aisner

Paul Chang

## TABLE OF CONTENTS

Introduction . . . . .	xv
------------------------	----

### Chapter 1: NEW APPROACHES TO THE DIAGNOSIS AND CLASSIFICATION OF THE NON-HODGKIN'S LYMPHOMAS

Elaine S. Jaffe, Raul C. Braylan, Koji Nanba and Costan W. Berard

Introduction . . . . .	1
Lymphomas Originating from B Lymphocytes . . . . .	3
Localization of T Cells in Nodular Lymphomas	
Nodes . . . . .	5
Spleen . . . . .	7
Internodular Areas . . . . .	8
Well Differentiated Lymphomas . . . . .	9
Intermediate Differentiation . . . . .	9
Histologic Features . . . . .	9
Histochemical Features . . . . .	10
Burkitt's Lymphomas . . . . .	11
Lymphomas of T-Cell Origin . . . . .	11
Lymphoblastic Lymphomas . . . . .	11
Large Cell Lymphomas . . . . .	13
Surface Markers . . . . .	16
Tumor Overgrowth or Recurrence . . . . .	16
T-Cell Markers . . . . .	17
Histiocytic Origin . . . . .	17
"Null" Cells . . . . .	17
Summary . . . . .	18

### Chapter 2: STAGING AND TREATMENT OF NON-HODGKIN'S LYMPHOMAS

Charles H. Diggs

#### STAGING OF NON-HODGKIN'S LYMPHOMAS

Introduction . . . . .	24
Clinical Manifestations . . . . .	24
Staging Procedures . . . . .	25
Blood Tests . . . . .	28

Radiology and Nuclear Medicine Studies . . . . .	29
Scans . . . . .	31
Other Tests . . . . .	32
Pathologic Examinations . . . . .	33
Final Impact of Staging . . . . .	33
<b>TREATMENT OF NON-HODGKIN'S LYMPHOMAS</b>	
General . . . . .	34
Surgery . . . . .	35
Radiotherapy . . . . .	36
Adjuvant Chemotherapy . . . . .	38
Total Body Irradiation . . . . .	39
Chemotherapy . . . . .	40
Re-staging . . . . .	44
Maintenance . . . . .	45
Conclusions and Recommendations . . . . .	45
Stage I & II Any Histology . . . . .	45
Stage IE Any Histology . . . . .	45
Stage III or IV DPDL, DM, DHL, NH . . . . .	45
Stage III or IV DWDL; NPDL, NM . . . . .	46

**Chapter 3: CURRENT ISSUES IN THE MANAGEMENT OF PATIENTS  
WITH HODGKIN'S DISEASE**

**Peter H. Wiernik**

Introduction . . . . .	51
Combined Modality Approach to Hodgkin's Disease	
Primarily Confined to Lymph Nodes . . . . .	52
Complications of Treatment . . . . .	56
Endocrine Complications . . . . .	56
Cardiovascular Complications . . . . .	56
Pulmonary Complications . . . . .	56
Reproductive Dysfunction . . . . .	57
Combination Chemotherapy Sequelae . . . . .	57
Thoughts for the Future . . . . .	57

**Chapter 4: THE ROLE OF RADIATION THERAPY IN THE MANAGEMENT  
OF CANCER OF THE HEAD AND NECK**

Ralph M. Scott

Introduction . . . . .	62
Therapeutic Alternatives According to Site	
Oral Cavity . . . . .	62
Paranasal Sinuses . . . . .	62
Nasopharynx . . . . .	63
Oropharynx . . . . .	63
Hypopharynx . . . . .	63
Glottis . . . . .	63
Salivary Glands . . . . .	64
Other General Approaches . . . . .	64
Equipment for Radiotherapy . . . . .	64
Factors Determining Response to Radiotherapy	
Anoxia . . . . .	64
Size and Origin of Tumors . . . . .	65
Local Failure of Treatment . . . . .	66
Combined Modality Treatment	
General Considerations . . . . .	66
Radiotherapy and Surgery . . . . .	66
Radiation and Chemotherapy . . . . .	67
Summary . . . . .	67

**Chapter 5: SYSTEMIC CHEMOTHERAPY IN ADVANCED HEAD AND NECK  
CANCER**

Franco M. Muggia and Marcel Rozenzweig

Introduction . . . . .	69
Single Agent Chemotherapy . . . . .	69
Methotrexate . . . . .	69
Bleomycin . . . . .	71
Cis-diamminedichloroplatinum II . . . . .	73
Other Drugs . . . . .	75
Combination Chemotherapy . . . . .	75
Other Areas of Investigation . . . . .	79
Immunotherapy . . . . .	79

Intraarterial (IA) Chemotherapy . . . . .	79
Combined Radiotherapy and Chemotherapy . . . . .	80
Conclusion . . . . .	80

## Chapter 6: CARCINOMA OF THE THYROID

Stephen C. Schimpff

Epidemiology . . . . .	88
Pathology . . . . .	88
Papillary-Follicular . . . . .	88
Anaplastic . . . . .	89
Medullary . . . . .	89
Metastases to Thyroid . . . . .	89
Prognostic Factors . . . . .	90
Pathogenesis	
Chronic Stimulation . . . . .	90
Irradiation . . . . .	91
Treatment of Well Differentiated Thyroid Carcinomas	
Treatment Alternatives . . . . .	92
Surgery versus Surgery + RAI . . . . .	93
Cytotoxic Drug Therapy . . . . .	95
Medullary Carcinoma of the Thyroid . . . . .	95
Sipple's Syndrome . . . . .	95
Hormone Abnormalities in Medullary Carcinoma . . . . .	96
Patterns of Presentation . . . . .	97
Therapy of Medullary Carcinoma . . . . .	97
Screening for Medullary Carcinoma . . . . .	98
Summary . . . . .	99

## Chapter 7: COMPUTED TOMOGRAPHY IN THE EVALUATION OF ABDOMINAL MALIGNANCY

David H. Stephens and Patrick F. Sheedy, II

Introduction . . . . .	103
Clinical Applications . . . . .	103
Liver and Biliary Tree . . . . .	105
Pancreas . . . . .	107

Adrenal Glands . . . . .	109
Kidneys . . . . .	110
Abdominal Lymphadenopathy . . . . .	111
Other Abdominal Tumors. . . . .	111
Summary . . . . .	114

## Chapter 8: MANAGEMENT OF GASTRIC AND PANCREATIC CANCER

J.J. Gullo, M. Citron, F.P. Smith, J.S. Macdonald and P.S. Schein

### GASTRIC CARCINOMA

Introduction . . . . .	119
Prognostic Determinants . . . . .	119
Therapy for Locally Advanced Disease	
Radiation Therapy . . . . .	120
Chemotherapy . . . . .	120
Chemotherapy of Disseminated Disease	
General . . . . .	121
5-Fluorouracil . . . . .	121
Mitomycin-C . . . . .	121
Nitrosoureas . . . . .	122
Anthracyclines . . . . .	122
Other Agents . . . . .	122
Combination Chemotherapy . . . . .	122
BCNU + 5-FU . . . . .	123
Methyl-CCNU + 5-FU . . . . .	123
5-FU, Mitomycin-C and Cytosine Arabinoside . . . . .	124
5-FU, Adriamycin and Mitomycin-C (FAM) . . . . .	124
Future Directions for Gastric Cancer . . . . .	126

### CANCER OF THE PANCREAS

Introduction . . . . .	126
Locally Advanced Carcinoma of the Pancreas	
Interstitial Irradiation . . . . .	127
External Beam Irradiation . . . . .	127
Chemotherapy and Radiation Therapy . . . . .	128
Other Radiation Therapy Approaches . . . . .	130
Therapy of Advanced Pancreatic Cancer	
General . . . . .	130
Single Agent Chemotherapy in Pancreatic Cancer . . . . .	131



Combination Chemotherapy in Pancreatic Cancer . . . . . 132  
Conclusion . . . . . 135

**Chapter 9: CHEMOTHERAPEUTIC MANAGEMENT OF BLADDER CANCER**

Donald J. Higby

Introduction . . . . . 142  
Indications for Chemotherapy  
    Chemotherapy for Advanced Disease . . . . . 142  
    Adjuvant Chemotherapy . . . . . 143  
    Adriamycin . . . . . 144  
    Cis-platinum diammine dichloride . . . . . 145  
    Cyclophosphamide . . . . . 146  
    5-Fluorouracil . . . . . 146  
    Other Agents . . . . . 147  
Combination Chemotherapy for Transitional Cell Carcinoma of the Bladder . 147  
Conclusions and Prospectus . . . . . 149

**Chapter 10: MAMMOGRAPHY**

Erlinda S. McCrea

Historical Perspective . . . . . 153  
Radiation Dosage  
    Technique and Dose . . . . . 154  
    Dose and Complications . . . . . 154  
Indications for Mammography . . . . . 155  
    Indications for Initial Mammography . . . . . 155  
    Indications for Serial Studies . . . . . 155  
    Mammography for Screening . . . . . 156  
Mammographic Features of Breast Cancer . . . . . 156  
    Mass . . . . . 156  
    Calcifications . . . . . 161  
    Duct Patterns . . . . . 161  
Differential Diagnosis of Breast Cancer on Mammography  
    Cysts . . . . . 162  
    Fibroadenoma . . . . . 162  
    Sclerosing Adenosis . . . . . 163  
    Breast Abscess . . . . . 163

Fat Necrosis . . . . . 164  
 Metastatic Disease to the Breast . . . . . 164  
 Biopsy Scars . . . . . 165  
 Mammographic Needle Localization . . . . . 165  
 Specimen Radiography . . . . . 167  
 Summary . . . . . 167

**Chapter 11: BREAST PARENCHYMAL PATTERNS ON MAMMOGRAPHY AND THEIR RELATIONSHIP TO CARCINOMA**

John N. Wolfe

Introduction . . . . . 171  
 Classification . . . . . 172  
 Correlation of Classification and Cancer . . . . . 176  
 Prevalent Versus Incident Carcinomas  
 Distinction . . . . . 177  
 Correlation of Risk Factors and Incident Carcinoma . . . . . 178  
 Correlation of Parenchymal Patterns with Histopathology . . . . . 179  
 Conclusions . . . . . 181

**Chapter 12: INITIAL MANAGEMENT OF CARCINOMA OF THE BREAST WITH RADIATION THERAPY INSTEAD OF MASTECTOMY**

Leonard R. Prosnitz

Introduction . . . . . 183  
 Radiologic Basis for Therapy . . . . . 184  
 Principles of Primary Radiation Therapy . . . . . 186  
 Results of Primary Radiotherapy . . . . . 187  
 Complications of Radiotherapy . . . . . 192  
 Relationship of Primary Radiation to Adjuvant Chemotherapy . . . . . 193  
 Conclusions . . . . . 194

**Chapter 13: THE SURGICAL TREATMENT OF PRIMARY BREAST CANCER**

Richard G. Margoese

The Radical Mastectomy . . . . . 197  
 Historical Perspective . . . . . 197

Current Perspective . . . . .	198
Treatment of Axillary Nodes . . . . .	198
Predictive Value of Axillary Lymph Nodes . . . . .	201
Lesser Surgical Procedures	
Rationale . . . . .	201
Results of Prior Trials . . . . .	202
Multicentric Breast Cancer	
Anatomical Multicentricity . . . . .	204
Clinical Multicentricity . . . . .	205
Investigative Surgical Approach . . . . .	206
Adjuvant Chemotherapy . . . . .	211
Conclusion . . . . .	212

Chapter 14: CLINICAL APPLICATIONS OF CELL KINETICS TO  
CHEMOTHERAPY OF HUMAN MALIGNANCY

Alvin M. Mauer

Introduction . . . . .	216
Cell Kinetics and Prognosis . . . . .	218
Chemotherapeutic Perturbation of Cell Population Kinetics . . . . .	218
Scheduling for Normal and Tumor Cell Response . . . . .	220
Summary . . . . .	221

Chapter 15: ADJUVANT THERAPY IN CHILDHOOD NEOPLASMS -  
AN OVERVIEW

W. W. Sutow

Introduction . . . . .	227
Wilms' Tumor	
Early Studies . . . . .	228
National Wilms' Tumor Study Group . . . . .	229
NWTS-1 . . . . .	230
NWTS-2 . . . . .	231
Rhabdomyosarcoma	
Background . . . . .	232
Intergroup Rhabdomyosarcoma Study . . . . .	233
Planning for Special Sites . . . . .	234

Osteosarcoma	
Background . . . . .	235
Adjuvant Chemotherapy . . . . .	236

## Chapter 16: AN OVERVIEW OF ADJUVANT THERAPY IN MAN

Emil J. Freireich

Introduction . . . . .	244
The Management of Systemic Cancer . . . . .	244
Early Treatment vs Late Treatment . . . . .	245
How to Differentiate Systemic from Local Cancer . . . . .	247
Which Modality of Cancer Treatment is the "Adjuvant"? . . . . .	247
The Requirements for Inclusion of Chemotherapy in the Multimodal Management of Malignancy . . . . .	249
Adjuvant Therapy Lessons from the Treatment of Acute Leukemia . . . . .	250
Treatment of the Patient Who Has No Evidence of Residual Disease . . . . .	252
Summary . . . . .	253

## Chapter 17: AN OVERVIEW OF UNCONVENTIONAL (FRAUDULENT) TREATMENTS OF CANCER

Daniel S. Martin

Introduction . . . . .	256
Nutrition and Cancer . . . . .	256
Nutritional Misinformation . . . . .	257
Why Are People So Vulnerable to Exploitation in the Field of Nutrition . . . . .	258
The "Freedom of Choice" Argument is a Consumer Protection Trap . . . . .	259
The Unscrupulous and the Misguided Physician . . . . .	260
The Testimonial, the Anecdote, and the Placebo Effect . . . . .	261
The "Terminal" Argument . . . . .	261
The Unconventional (Fraudulent) Treatments for Cancer . . . . .	263
Laetrile . . . . .	263

Why Do People Place Their Lives, or the Lives of Their  
Loved Ones on a Treatment Which is Generally Rejected  
as a Fraud by Almost Everyone Trained and Experienced in  
Cancer Research and Treatment? . . . . . 264

How Unconventional (Fraudulent) Treatments of Cancer are  
Successfully Promoted - How Laypeople are Deceived -  
Laetrile as an Example . . . . . 265  
"Scientific" Claims Without Supporting Data . . . . . 265  
Testimonials for Clinical Evidence . . . . . 265  
Claim is Made that Cancer Causation is Due to Diet . . . . . 266  
Claim of Non-Toxicity . . . . . 266  
Claim for Equality of Opinion . . . . . 266  
Claim Persecution as Scientific Pioneers . . . . . 267  
Claim "Establishment" Prejudice and a Conspiracy. . . . . 267  
Lack of Scientific Publication . . . . . 267  
Claim Public Figures as Supporters . . . . . 267  
Claims for Political Support (In Contrast to Medical Support) . . . 267  
Claims (In Terms of Pseudo-Scientific Jargon) That  
    the Method of Treatment Can Only be Done by Themselves . . 268  
    The "Big" Lie . . . . . 268  
Who Makes, or Should Make, Scientific Policy? . . . . . 268

Contributing Authors . . . . . 270

NEW APPROACHES TO THE DIAGNOSIS AND  
CLASSIFICATION OF THE NON-HODGKIN'S LYMPHOMAS

Elaine S. Jaffe, M.D., Raul C. Braylan, M.D.,  
Koji Nanba, M.D., Costan W. Berard, M.D.  
National Cancer Institute  
National Institutes of Health  
Bethesda, Maryland

INTRODUCTION

Malignant lymphomas have been traditionally classified morphologically. The classification published by Rappaport in 1966 (1), with minor modifications (2,3), has been the one most widely employed for clinicopathologic studies (table 1).

Table 1  
CLASSIFICATION OF NON-HODGKIN'S LYMPHOMAS (1-3)

Nodular

Lymphocytic, poorly differentiated  
Mixed lymphocytic-histiocytic  
Histiocytic

Diffuse

Lymphocytic, well differentiated  
Lymphocytic, intermediate differentiation  
Lymphocytic, poorly differentiated  
Mixed lymphocytic-histiocytic  
Histiocytic  
Undifferentiated (Burkitt's type)  
Undifferentiated, pleomorphic (non-Burkitt's)  
Lymphoblastic

However, with the recognition of malignant lymphomas as neoplastic disorders of the immune system, a new functional approach has been undertaken for the classification and understanding of these tumors. Immunological knowledge and techniques have been brought to bear on clinical and pathological problems. For example, the concepts of homing and "traffic" of normal lymphocytes help to

explain the patterns of spread of these tumors. Likewise, the immunological deficits manifested by these patients relate to which component of the immune system is affected by neoplasia. One major area of investigation which typifies this approach has been the study of the neoplastic cells themselves, both for the presence of cell surface markers as well as in functional assays (table 2).

Table 2  
TECHNIQUES USED IN THE INVESTIGATION  
OF LYMPHORETICULAR MALIGNANCIES

1. Membrane bound immunoglobulins - SIg  
individual light and heavy chains  
in vitro synthesis
2. Intracytoplasmic immunoglobulin  
immunofluorescence  
immunoperoxidase
3. Complement receptors - EAC rosettes
4. Receptors for cytophilic antibody - IgGEA rosettes
5. Spontaneous SRBC binding - E rosettes
6. In vitro phagocytosis
7. Cytochemical markers  
"non-specific" esterases  
acid phosphatase  
beta-glucuronidase  
alkaline phosphatase
8. Terminal deoxynucleotidyl transferase (TdT)
9. In vitro culture of neoplastic cells

By analogy with normal cells, many of the tumors have been classified according to their presumptive cells of origin: T lymphocyte, B lymphocyte, or monocyte-macrophage (table 3).

Table 3  
SUMMARY OF CELL SURFACE MARKERS IN  
LYMPHORETICULAR MALIGNANCIES

Well-differentiated lymphocytic malignancies	B lymphocytic
Chronic lymphocytic leukemia	
Well-differentiated lymphocytic lymphoma	
Waldenstrom's macroglobulinemia	
Lymphocytic lymphoma, intermediate	B lymphocytic
Nodular (Follicular) lymphoma	B lymphocytic
Burkitt's lymphoma	B lymphocytic
Mycosis fungoides	T lymphocytic
Sezary syndrome	
Lymphoblastic lymphoma	T lymphocytic
Acute lymphoblastic leukemia (25%)	
Histiocytic lymphomas	Heterogenous
Malignant histiocytosis	Histiocytic

#### LYMPHOMAS ORIGINATING FROM B LYMPHOCYTES

Most non-Hodgkin's lymphomas in adults appear to be of B lymphocytic origin. However, different B-cell populations display subtle variations in their surface markers and have thus permitted the assignment of some lymphomas to particular subpopulations. The cells of the lymphoid follicle are characterized by abundant surface immunoglobulin (SIg) and avid complement receptors, but as a B cell differentiates towards a plasma cell there is a loss of both of these surface membrane markers. Of course, intermediate stages also are present in which SIg is reduced in density and complement receptors are sparse.

Nodular lymphomas are cytologically and immunologically tumors composed of follicular B lymphocytes (4-6). These tumors are a major category of non-Hodgkin's lymphomas in adults, representing approximately 50% of all cases. Clinically these tumors are most often generalized at diagnosis, presenting as stage III or IV disease. Peripheral lymph node groups are frequently involved as are mesenteric nodes, bone marrow and liver (7). However, in spite of its



widespread dissemination, this disease may be compatible with relatively long survival, even without aggressive therapy (8). This favorable prognosis appears to be particularly true of the nodular lymphomas of poorly differentiated lymphocytic type, in which the tendency of these tumors to disseminate seems related to the capacity of the neoplastic lymphoid cells to migrate or home like normal lymphoid cells (9). The large cells or "histiocytes" within these tumors represent the proliferative component and, when such cells are present in increased numbers, as in nodular lymphomas of mixed or histiocytic type, the disease is associated with a more aggressive clinical course (10), especially if one does not achieve a complete remission.

Cytologically nodular lymphomas reflect the composition of a normal germinal center (11-12). Immunologically, these tumors also have the characteristics of follicular B lymphocytes. We have previously published on the surface membrane markers of nodular lymphomas and have shown avid complement receptors on the neoplastic cells, also a feature of normal follicular B lymphocytes (4). Other authors have found easily detectable SIg, usually of the IgM class with or without IgD (5,6). Our studies have now been expanded to include a total of 49 specimens from 36 patients and earlier observations have been confirmed (table 4). Strong binding of erythrocyte-antibody complement rosettes (EAC), both in suspensions and on frozen sections, was seen in 48 of the 49. Thirty-two studied for SIg had bright staining of the neoplastic cells in all but one. Fifteen were evaluated for individual light and heavy chains, i.e.,  $\kappa$  and  $\lambda$ , as well as IgM, IgG and IgA. In all instances the SIg was monoclonal with only a single light chain. IgM was the heavy chain in 13 of the 15. Only kappa light chains were found in two, but these were not studied for IgD. Two of five specimens studied for IgD were positive and in one of these both IgD and IgM were identified with only kappa light chains. The coexistence of surface bound IgD and IgM has been reported in other B lymphocytic tumors, most commonly in chronic lymphocytic leukemia, and does not contradict the monoclonality of these neoplasms (13). When an anti-idiotypic antibody was prepared, the IgD and IgM were shown to be of the same idiootype and even to share the same antibody specificity.